Hospital
The Johns Hopkins Hospital
The Johns Hopkins Hospital was paid $19.90M by Medicaid between Jan 2018 and Dec 2024, across 316 billing codes. Its largest line is 99284, emergency room visit (serious) — 13% of everything it billed.
33Billing provider infoTHE JOHNS HOPKINS HOSPITAL
BALTIMORE, MD 21287
BALTIMORE, MD 21287
33aNPI1578597993assigned 07/10/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$19.90M
24GClaims753,076
24DCodes billed316
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Maryland
Rank by total paid#1 of 69
Median peer was paid$870K
This provider vs. median23×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 163,159 | $6.98M | |
| 2019 | 134,081 | $3.30M | |
| 2020 | 71,925 | $1.85M | |
| 2021 | 97,386 | $2.24M | |
| 2022 | 114,610 | $2.29M | |
| 2023 | 99,032 | $1.94M | |
| 2024incomplete | 72,883 | $1.32M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 13% | 8,498 | 7,327 | $2.65M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 12% | 4,993 | 4,364 | $2.29M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 9.9% | 101,187 | 78,078 | $1.98M |
| 87536 | 9.2% | 8,265 | 7,545 | $1.83M | |
| G0378 | Hospital observation service, per hour | 8.3% | 4,624 | 3,998 | $1.66M |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | 4.3% | 1,149 | 994 | $859K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 4.1% | 5,153 | 4,429 | $810K |
| P9016 | Red blood cells, leukocytes reduced, each unit | 3.7% | 1,668 | 1,369 | $741K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 3.1% | 8,214 | 5,845 | $609K |
| 36512 | 3.1% | 1,198 | 1,000 | $609K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 2.4% | 5,583 | 3,384 | $482K |
| 80053 | Comprehensive metabolic panel | 1.8% | 44,771 | 31,019 | $364K |
304 more codes
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.3% | 5,536 | $265K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.3% | 2,884 | $256K |
| J2794 | Injection, risperidone (risperdal consta), 0.5 mg | 1.1% | 1,194 | $228K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.1% | 6,137 | $210K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,894 | $192K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 3,190 | $181K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,789 | $163K |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 5,360 | $144K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 777 | $136K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,508 | $127K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 3,192 | $113K |
| 36430 | <1% | 512 | $107K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 41,237 | $107K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,963 | $103K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 5,163 | $94K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 4,076 | $90K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,900 | $88K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 554 | $87K |
| 93971 | <1% | 630 | $85K | |
| 87901 | <1% | 173 | $84K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,274 | $80K |
| 71250 | <1% | 1,361 | $80K | |
| 90837 | Psychotherapy session, about an hour | <1% | 1,578 | $71K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,831 | $70K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 7,407 | $70K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 2,510 | $62K |
| 36415 | Collection of venous blood by venipuncture | <1% | 29,102 | $57K |
| 94010 | <1% | 567 | $56K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 93 | $56K |
| 87070 | <1% | 1,581 | $53K | |
| 97161 | <1% | 800 | $51K | |
| 36591 | <1% | 851 | $50K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,336 | $47K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 417 | $47K |
| 87340 | <1% | 1,066 | $46K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 6,150 | $46K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,152 | $45K |
| 87522 | Neg quan hep c or qual rna | <1% | 692 | $38K |
| 71045 | Radiologic examination, chest; single view | <1% | 3,256 | $36K |
| 86359 | <1% | 2,316 | $34K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,969 | $32K |
| 96415 | <1% | 1,044 | $32K | |
| 93922 | <1% | 183 | $27K | |
| 82803 | <1% | 1,798 | $25K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,531 | $24K |
| 81001 | <1% | 12,154 | $23K | |
| 86850 | <1% | 6,094 | $22K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 63 | $21K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 436 | $21K |
| 97162 | <1% | 306 | $20K | |
| C1769 | Guide wire | <1% | 1,630 | $20K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,234 | $19K |
| 97597 | <1% | 191 | $19K | |
| 86922 | <1% | 1,276 | $18K | |
| 73030 | <1% | 415 | $17K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 3,531 | $17K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 2,484 | $17K |
| 86902 | <1% | 150 | $17K | |
| C9399 | Unclassified drugs or biologicals | <1% | 318 | $17K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 28 | $15K |
| V2632 | Posterior chamber intraocular lens | <1% | 1,497 | $14K |
| 84484 | <1% | 9,749 | $14K | |
| 92083 | <1% | 285 | $13K | |
| 85027 | <1% | 6,354 | $13K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 43 | $13K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 2,115 | $13K |
| 52000 | <1% | 47 | $12K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 210 | $12K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 240 | $12K |
| 73630 | <1% | 381 | $12K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,686 | $12K |
| 87077 | <1% | 1,167 | $12K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 5,011 | $11K |
| J3535 | Drug administered through a metered dose inhaler | <1% | 486 | $11K |
| J2704 | Injection, propofol, 10 mg | <1% | 10,767 | $11K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,578 | $11K |
| 87497 | <1% | 46 | $10K | |
| J3490 | Unclassified drugs | <1% | 8,681 | $10K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 8,580 | $10K |
| 92557 | <1% | 320 | $10K | |
| 90714 | <1% | 377 | $10K | |
| 72082 | <1% | 38 | $10K | |
| 96402 | <1% | 281 | $10K | |
| 73560 | <1% | 362 | $10K | |
| 96367 | <1% | 760 | $9K | |
| 90686 | <1% | 2,740 | $9K | |
| 92567 | <1% | 138 | $9K | |
| 93017 | <1% | 266 | $9K | |
| 90670 | <1% | 121 | $9K | |
| 86140 | <1% | 2,066 | $9K | |
| 87631 | <1% | 514 | $8K | |
| P9040 | Red blood cells, leukocytes reduced, irradiated, each unit | <1% | 22 | $8K |
| 77066 | Tomosynthesis, mammo | <1% | 24 | $8K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 22 | $8K |
| 87799 | <1% | 288 | $8K | |
| 77065 | Tomosynthesis, mammo | <1% | 27 | $7K |
| 93970 | <1% | 40 | $7K | |
| 80061 | Lipid panel | <1% | 4,239 | $7K |
| 86147 | <1% | 160 | $7K | |
| 96401 | <1% | 243 | $7K | |
| 73130 | <1% | 174 | $7K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 7,595 | $6K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 655 | $6K |
| 92133 | <1% | 195 | $6K | |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 217 | $6K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 13,452 | $6K |
| 90732 | <1% | 175 | $6K | |
| 83021 | <1% | 2,176 | $6K | |
| A9270 | Non-covered item or service | <1% | 58,230 | $6K |
| 83880 | <1% | 4,266 | $5K | |
| 83605 | <1% | 4,627 | $5K | |
| 74183 | <1% | 15 | $5K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,650 | $5K |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 1,997 | $4K |
| 82728 | <1% | 2,531 | $4K | |
| 90677 | <1% | 187 | $4K | |
| 97165 | <1% | 78 | $4K | |
| 90662 | <1% | 1,051 | $4K | |
| 90734 | <1% | 99 | $4K | |
| 88307 | <1% | 139 | $4K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 11,384 | $4K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 4,261 | $4K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 10,170 | $4K |
| 76377 | <1% | 304 | $4K | |
| 86923 | <1% | 998 | $4K | |
| 87040 | <1% | 194 | $4K | |
| 73502 | <1% | 77 | $3K | |
| 85046 | <1% | 3,255 | $3K | |
| 73110 | <1% | 49 | $3K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,059 | $3K |
| 82105 | <1% | 238 | $3K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,200 | $3K |
| 74018 | <1% | 26 | $3K | |
| 86780 | <1% | 1,855 | $3K | |
| 84439 | <1% | 2,140 | $3K | |
| 73610 | <1% | 69 | $2K | |
| 84702 | <1% | 1,628 | $2K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 62 | $2K |
| 86706 | <1% | 579 | $2K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 9,041 | $2K |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 27 | $2K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,225 | $2K |
| 85610 | <1% | 6,501 | $2K | |
| 67028 | Intravitreal injection of a pharmacologic agent | <1% | 15 | $2K |
| 91320 | <1% | 208 | $2K | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 445 | $2K |
| 87081 | <1% | 84 | $2K | |
| 87632 | <1% | 54 | $2K | |
| 88142 | <1% | 51 | $2K | |
| J1815 | Injection, insulin, per 5 units | <1% | 1,080 | $2K |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 445 | $2K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 640 | $2K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 36 | $2K |
| J1631 | Injection, haloperidol decanoate, per 50 mg | <1% | 1,238 | $2K |
| 84153 | <1% | 1,069 | $2K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,698 | $1K |
| 93350 | <1% | 16 | $1K | |
| 86901 | <1% | 5,818 | $1K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,600 | $1K |
| 93325 | <1% | 97 | $1K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 720 | $1K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 705 | $1K |
| 80197 | <1% | 2,379 | $1K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,274 | $1K |
| 86803 | <1% | 671 | $1K | |
| 83735 | <1% | 9,136 | $1K | |
| J7799 | Noc drugs, other than inhalation drugs, administered through dme | <1% | 600 | $1K |
| 84703 | <1% | 816 | $1K | |
| 85730 | <1% | 2,855 | $989.45 | |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | <1% | 93 | $889.78 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 448 | $876.52 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 753 | $852.83 |
| 88112 | <1% | 29 | $814.00 | |
| 86481 | <1% | 208 | $796.71 | |
| 76770 | <1% | 14 | $785.97 | |
| 83690 | <1% | 3,921 | $785.56 | |
| J7070 | Infusion, d5w, 1000 cc | <1% | 3,176 | $769.41 |
| 86900 | <1% | 5,845 | $733.89 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 310 | $733.88 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 531 | $724.22 |
| 76000 | <1% | 15 | $708.84 | |
| 82784 | <1% | 1,195 | $703.06 | |
| 91200 | <1% | 20 | $702.46 | |
| 82607 | <1% | 587 | $698.87 | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 15 | $640.78 |
| 97116 | <1% | 116 | $624.12 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,992 | $576.91 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 505 | $565.32 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 22 | $537.38 |
| 87205 | <1% | 452 | $506.56 | |
| 86704 | <1% | 60 | $496.79 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 138 | $490.21 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 4,830 | $487.69 |
| 82570 | <1% | 2,262 | $474.97 | |
| 76642 | <1% | 26 | $457.46 | |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 82 | $443.03 |
| 86361 | <1% | 2,072 | $426.47 | |
| 82043 | <1% | 1,331 | $401.05 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,448 | $394.59 |
| 90739 | <1% | 29 | $392.68 | |
| 86593 | <1% | 16 | $391.52 | |
| G0008 | Administration of influenza virus vaccine | <1% | 56 | $383.11 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 471 | $373.83 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 1,895 | $349.39 |
| 88185 | <1% | 20 | $346.73 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 859 | $330.52 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 771 | $321.73 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 3,723 | $321.14 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 116 | $309.30 |
| 82550 | <1% | 1,556 | $299.12 | |
| 85652 | <1% | 2,084 | $291.48 | |
| 90480 | <1% | 28 | $272.87 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,161 | $272.37 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 2,507 | $260.43 |
| 84132 | <1% | 2,741 | $253.74 | |
| 87186 | <1% | 630 | $238.67 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 35 | $225.63 |
| 94727 | <1% | 43 | $220.04 | |
| 94729 | <1% | 33 | $212.45 | |
| 85613 | <1% | 137 | $206.20 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 12 | $195.93 |
| 98966 | <1% | 54 | $183.92 | |
| 83540 | <1% | 1,879 | $180.24 | |
| 85379 | <1% | 876 | $179.73 | |
| 84100 | <1% | 4,657 | $172.01 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 1,176 | $159.70 |
| 84156 | <1% | 2,183 | $145.73 | |
| 86160 | <1% | 299 | $138.01 | |
| 85660 | <1% | 501 | $135.96 | |
| 84466 | <1% | 1,871 | $131.83 | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 37 | $130.19 |
| 82077 | <1% | 212 | $122.15 | |
| 83970 | <1% | 976 | $121.76 | |
| 85018 | <1% | 33 | $102.33 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 300 | $98.67 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 25 | $94.31 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 217 | $92.66 |
| 87660 | <1% | 26 | $85.37 | |
| 98968 | <1% | 13 | $80.21 | |
| J2680 | Injection, fluphenazine decanoate, up to 25 mg | <1% | 185 | $79.40 |
| 84165 | <1% | 806 | $64.01 | |
| 90653 | <1% | 15 | $62.22 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 13 | $61.76 |
| 83521 | <1% | 656 | $45.29 | |
| 86225 | <1% | 184 | $41.41 | |
| 82565 | <1% | 303 | $37.69 | |
| 83883 | <1% | 142 | $32.84 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 162 | $29.68 |
| 83615 | <1% | 471 | $23.42 | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 19 | $20.49 |
| 88313 | <1% | 12 | $19.84 | |
| 84295 | <1% | 467 | $19.08 | |
| 84550 | <1% | 1,164 | $18.98 | |
| 80164 | <1% | 14 | $12.22 | |
| 82465 | <1% | 77 | $7.80 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 892 | $2.70 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 441 | $0.03 |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 30 | $0.01 |
| G8984 | Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 16 | $0.01 |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | 0% | 14 | $0.00 |
| G1012 | Clinical decision support mechanism agilemd, as defined by the medicare appropriate use criteria program | 0% | 3,420 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 476 | $0.00 |
| 96417 | 0% | 1,332 | $0.00 | |
| 84403 | 0% | 16 | $0.00 | |
| 0054A | 0% | 85 | $0.00 | |
| J9201 | Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 0% | 16 | $0.00 |
| 86334 | 0% | 12 | $0.00 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 79 | $0.00 |
| 82248 | 0% | 12 | $0.00 | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 53 | $0.00 |
| 0002A | 0% | 60 | $0.00 | |
| A4649 | Surgical supply; miscellaneous | 0% | 29 | $0.00 |
| J1453 | Injection, fosaprepitant, 1 mg | 0% | 20 | $0.00 |
| 93356 | 0% | 25 | $0.00 | |
| 87075 | 0% | 32 | $0.00 | |
| 82542 | 0% | 56 | $0.00 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 30 | $0.00 |
| 90853 | Group psychotherapy (other than of a multiple-family group) | 0% | 75 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 28 | $0.00 |
| 88173 | 0% | 13 | $0.00 | |
| G8990 | Other physical or occupational therapy primary functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 15 | $0.00 |
| 84154 | 0% | 12 | $0.00 | |
| 86769 | 0% | 52 | $0.00 | |
| J0613 | Injection, calcium gluconate (wg critical care), not therapeutically equivalent to j0612, 10 mg | 0% | 81 | $0.00 |
| J0610 | Injection, calcium gluconate (fresenius kabi), per 10 ml | 0% | 203 | $0.00 |
| 88342 | 0% | 306 | $0.00 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 403 | $0.00 |
| 87430 | 0% | 12 | $0.00 | |
| 88184 | 0% | 21 | $0.00 | |
| 80220 | 0% | 14 | $0.00 | |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 47 | $0.00 |
| 96376 | 0% | 56 | $0.00 | |
| 0001A | 0% | 111 | $0.00 | |
| 80069 | 0% | 13 | $0.00 | |
| 90656 | 0% | 144 | $0.00 | |
| 36000 | 0% | 13 | $0.00 | |
| 88341 | 0% | 12 | $0.00 | |
| J0611 | Injection, calcium gluconate (wg critical care), per 10 ml | 0% | 16 | $0.00 |
| 82378 | 0% | 13 | $0.00 | |
| 86255 | 0% | 17 | $0.00 | |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 12 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 48 | $0.00 |
| G8991 | Other physical or occupational therapy primary functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 16 | $0.00 |
| 0012A | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMILLER, REDONDA (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| The Johns Hopkins Hospital | Baltimore, MD | $6.68M |
| The Johns Hopkins Hospital | Baltimore, MD | $139K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.